glp-1 drugs impact on energy levels Frontiers American drugmakers pushed GLP1 therapies

These incretin effects explain the initially surprising weight loss observed in the treatment groups of the cardiovascular trials, with subjects taking GLP-1/GIP agonists losing from 3% to 12% of their body weight

Parthsarathy et al

In addition to lowering the levels of blood glucose, as shown in Figure 1 , GLP-1RAs have also been shown to have a positive effect on multiple human tissues

After some months of deliberation Knudsen decided the best way forward was to find something that could protect the GLP-1 molecule

doi: 10.2337/db07-1124 40 TanQAkindehinSEOrssoCEWaldnerRCDiMarchiRDMllerTDet al

GLP-1RA (such as exendin-4) treatment can reduce the size of MI impacted cardiac volume in rats, inhibit ventricular dilation, myocardial fibrosis and hypertrophy in vivo [72]